Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
about
Slit/Robo pathway: a promising therapeutic target for cancerEfficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity.Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.Drugs acting on homeostasis: challenging cancer cell adaptation.mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer.Denoising perturbation signatures reveal an actionable AKT-signaling gene module underlying a poor clinical outcome in endocrine-treated ER+ breast cancer.High basal Wnt signaling is further induced by PI3K/mTor inhibition but sensitive to cSRC inhibition in mammary carcinoma cell lines with HER2/3 overexpression.Glycyrrhizic acid inhibits leukemia cell growth and migration via blocking AKT/mTOR/STAT3 signaling.Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells.Dose-dependent benefits of quercetin on tumorigenesis in the C3(1)/SV40Tag transgenic mouse model of breast cancer.Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies.Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer.mTOR function and therapeutic targeting in breast cancer.Targeting Programmed Cell Death Using Small-Molecule Compounds to Improve Potential Cancer Therapy.Targeting the mTOR pathway in breast cancer.Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells.Hyperactive mTOR and MNK1 phosphorylation of eIF4E confer tamoxifen resistance and estrogen independence through selective mRNA translation reprogramming.Horizontal Transfer of Tamoxifen Resistance in MCF-7 Cell Derivates: Proteome Study.miR-99a-5p acts as tumor suppressor via targeting to mTOR and enhances RAD001-induced apoptosis in human urinary bladder urothelial carcinoma cells.Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date.Involvement of multiple cellular pathways in regulating resistance to tamoxifen in BIK-suppressed MCF-7 cells.16-Hydroxycleroda-3,13-dien-15,16-olide and N-Methyl-Actinodaphine Potentiate Tamoxifen-Induced Cell Death in Breast Cancer
P2860
Q27026113-54DE623A-9944-4794-A298-F74571710C82Q30313117-AC60D3A3-910F-471E-A808-79F5C8F29660Q33656801-E9CD5990-8858-47FC-85AE-B584868887D6Q34500113-90C3BA8A-236D-44F8-97DE-BE5B63A1EE1AQ35139024-B784E57F-D4FE-4BB2-A5C0-087839A9BDB2Q35446364-3114A6AF-C6A9-44E1-B5A3-EC8FC0AA22BAQ35709435-74B0F687-F066-4766-A649-AD62EAF954B8Q35854097-6ADD619C-3965-49C9-935B-5F694DBF09B8Q36078905-9FE3FFCC-30E9-49C7-A83A-601A8D7E8BB1Q36214982-56CF254A-D7A8-4C68-83E8-90326AC9A53DQ36933778-4A5C0C0E-9C53-4181-A262-5FD0559BBB2FQ37690890-7D8D6687-319E-4613-B3B3-234441087F52Q37743486-86B127D4-74F3-495F-B96B-E85C04673F98Q38881119-892BFEC4-F0CC-4774-A2D9-3DDD34489201Q39390640-AC68FC95-D5A1-4685-B4DA-59DDA866D6F7Q41457277-5EE2AB11-74F0-4F4E-A4BE-3EFAE9B51449Q41628138-8025FEC6-D91F-4D33-9908-1B363B88C76AQ47263046-0C7B3744-BB12-4D73-A237-AB3CF6B97D61Q47802521-667727C3-6A21-4593-80DF-E87B528A4F5FQ49425667-048B7D11-C001-4F9F-9F3F-86748A885B83Q49478004-4A2C21FE-07EB-452F-ACDA-446608FC4C43Q52952429-888615FD-1716-4782-8B34-4967E2E7B2F1Q58697456-5ACE46ED-366D-4924-913F-D62A490AEE0E
P2860
Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Impact of dual mTORC1/2 mTOR k ...... nce in breast cancer in vitro.
@en
Impact of dual mTORC1/2 mTOR k ...... nce in breast cancer in vitro.
@nl
type
label
Impact of dual mTORC1/2 mTOR k ...... nce in breast cancer in vitro.
@en
Impact of dual mTORC1/2 mTOR k ...... nce in breast cancer in vitro.
@nl
prefLabel
Impact of dual mTORC1/2 mTOR k ...... nce in breast cancer in vitro.
@en
Impact of dual mTORC1/2 mTOR k ...... nce in breast cancer in vitro.
@nl
P2093
P2860
P356
P1476
Impact of dual mTORC1/2 mTOR k ...... nce in breast cancer in vitro.
@en
P2093
Carol M Dutkowski
Denise Barrow
Huw J Mottram
Iain R Hutcheson
Nicola J Jordan
Robert I Nicholson
Sylvie M Guichard
P2860
P2888
P356
10.1186/BCR3604
P50
P577
2014-01-23T00:00:00Z
P5875
P6179
1051068164